EP4489585A1 - Composition pour le traitement d'une infection parasitaire ou virale dans un tube digestif et/ou respiratoire - Google Patents

Composition pour le traitement d'une infection parasitaire ou virale dans un tube digestif et/ou respiratoire

Info

Publication number
EP4489585A1
EP4489585A1 EP23717837.1A EP23717837A EP4489585A1 EP 4489585 A1 EP4489585 A1 EP 4489585A1 EP 23717837 A EP23717837 A EP 23717837A EP 4489585 A1 EP4489585 A1 EP 4489585A1
Authority
EP
European Patent Office
Prior art keywords
composition
acid
composition according
subject
dry weight
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
EP23717837.1A
Other languages
German (de)
English (en)
Inventor
Morten HARRINGTON RAAHOLT
Mikkel FLESSUM HARRINGTON RAAHOLT
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Vitality Innovation
Original Assignee
Vitality Innovation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vitality Innovation filed Critical Vitality Innovation
Publication of EP4489585A1 publication Critical patent/EP4489585A1/fr
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23K—FODDER
    • A23K50/00—Feeding-stuffs specially adapted for particular animals
    • A23K50/70—Feeding-stuffs specially adapted for particular animals for birds
    • A23K50/75—Feeding-stuffs specially adapted for particular animals for birds for poultry
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23K—FODDER
    • A23K10/00—Animal feeding-stuffs
    • A23K10/30—Animal feeding-stuffs from material of plant origin, e.g. roots, seeds or hay; from material of fungal origin, e.g. mushrooms
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23K—FODDER
    • A23K20/00—Accessory food factors for animal feeding-stuffs
    • A23K20/10—Organic substances
    • A23K20/158—Fatty acids; Fats; Products containing oils or fats
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23K—FODDER
    • A23K20/00—Accessory food factors for animal feeding-stuffs
    • A23K20/10—Organic substances
    • A23K20/174—Vitamins
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23K—FODDER
    • A23K20/00—Accessory food factors for animal feeding-stuffs
    • A23K20/20—Inorganic substances, e.g. oligoelements
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23K—FODDER
    • A23K50/00—Feeding-stuffs specially adapted for particular animals
    • A23K50/10—Feeding-stuffs specially adapted for particular animals for ruminants
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23K—FODDER
    • A23K50/00—Feeding-stuffs specially adapted for particular animals
    • A23K50/20—Feeding-stuffs specially adapted for particular animals for horses
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23K—FODDER
    • A23K50/00—Feeding-stuffs specially adapted for particular animals
    • A23K50/80—Feeding-stuffs specially adapted for particular animals for aquatic animals, e.g. fish, crustaceans or molluscs
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/105—Plant extracts, their artificial duplicates or their derivatives
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/115—Fatty acids or derivatives thereof; Fats or oils
    • A23L33/12—Fatty acids or derivatives thereof
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/15—Vitamins
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/16—Inorganic salts, minerals or trace elements
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/194—Carboxylic acids, e.g. valproic acid having two or more carboxyl groups, e.g. succinic, maleic or phthalic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4188—1,3-Diazoles condensed with other heterocyclic ring systems, e.g. biotin, sorbinil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4415—Pyridoxine, i.e. Vitamin B6
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/455—Nicotinic acids, e.g. niacin; Derivatives thereof, e.g. esters, amides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A61K31/51—Thiamines, e.g. vitamin B1
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/525—Isoalloxazines, e.g. riboflavins, vitamin B2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7135—Compounds containing heavy metals
    • A61K31/714—Cobalamins, e.g. cyanocobalamin, i.e. vitamin B12
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/26—Iron; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/54—Lauraceae (Laurel family), e.g. cinnamon or sassafras
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis

Definitions

  • the amount of salt and carboxylic acids will give a pH amounting to 2.0 to 7.5 when the composition is in form of a suspension.
  • the amount of salt and carboxylic acids will give a pH amounting to 2.0 to 7.5 when the composition is dissolved in water.
  • the amount of salt and carboxylic acids will give a pH amounting to 2.0 to 6.0 when the composition is dissolved in water.
  • the composition is a dietary supplement.
  • the composition is a pharmaceutical composition.
  • the dietary supplement for decreasing infectivity of a virus and/or a parasite in a subject .
  • the parasite is caused by a parasite with a hard-shelled life cycle stage where it forms a cyst and/or oocyst.
  • the parasite and/or the virus is comprised in the gastrointestinal system such as the alimentary tract and/or respiratory system of the subject.
  • the virus is selected from rotaviruses, adenoviruses, coronaviruses, Hepatitis A, Hepatitis E, Norovirus, Enterovirus and Poliovirus.
  • the parasite is selected from coccidiosis and giardiasis.
  • the fatty acids are selected from Sodium Caprylate, Potassium Sorbate, Sodium Formate, Sodium Butyrate, Sodium Acetate, Sodium Propionate and any combinations thereof wherein the composition is for use in preventing or treatment of a parasite comprised in the gastrointestinal system such as the alimentary tract and/or respiratory system of the subject.
  • the fatty acids are selected from Sodium Caprylate, Potassium Sorbate, Sodium Formate, Sodium Butyrate, Sodium Propionate and any combinations thereof wherein the composition is for use in preventing or treatment of a virus is comprised in the gastrointestinal system such as the alimentary tract and/or respiratory system of the subject.
  • the animal is selected from a ruminant, a horse, a race pigeon, a dog and a cat.
  • the composition is administrated as a daily dose in the range 25-500 mg dry weight / kg body weight or 0.5-10g per 20kg body weight
  • the first aspect is administrated as a daily dose of about 1g per 20kg body weight for use in reducing the risk of a parasitic infection and/or viral infection in a subject.
  • the composition is administrated as a daily dose of 2g- 10g per 20kg body weight for use in treatment of or aid in treatment of a parasitic infection and/or viral infection in a subject.
  • a method decreasing infectivity of a virus and/or a parasite in a subject comprising administering to the subject the composition according to the first aspect in a daily dose in the range from 25 to 500 mg dry weight / kg body weight of the subject.
  • a method for use in reducing the risk of and/or aid in treatment of a parasitic infection and/or viral infection in a subject comprising administering to the subject the composition according to the first aspect in a daily dose in the range from 25 to 500 mg dry weight / kg body weight of the subject.
  • a composition comprising one or more C1-C12 organic acid and/or its salt, an iron component, and B-vitamins for use in reducing the risk of and/or treatment of a parasitic infection and/or viral infection in a subject, wherein the B-vitamins is in an amount of 0-200 mg/g dry weight of the composition and the amount of B-vitamins corresponding to at least that which theoretically can be consumed during metabolism of the COOH-groups of the organic acid and wherein the organic acid is a carboxylic acid wherein the organic acid is a carboxylic acid with acidic properties according Bronsted definition of an acid which is a molecule that can donate a proton to another molecule.
  • the composition does not comprise D/L-carnitine.
  • D/L-carnitine is derived from lysine and methionine and is involved in metabolism of fatty acids.
  • the Cl -Cl 2 organic acid is a fatty acid and/or its salts.
  • the iron component is ferrous fumarate.
  • the fatty acids are selected from Caprylic acid (C8), Sorbic acid (C6), formic acid (Cl), Propionic acid (C3), Butyric acid (C4), acetic acid (C2) and any combinations thereof.
  • the at least one organic acid is formic acid and its salt.
  • the fatty acids are selected from Sodium Caprylate, Potassium Sorbate, Sodium Formate, Sodium Butyrate, Sodium Propionate and any combinations thereof
  • composition is administration by inhalation or intranasal application in the state of powder, suspension, gelsuspension, supplemented directly to food/feed or is swallowed as a tablet or capsule.
  • the parasite is caused by a parasite with a hard-shelled life cycle stage where it forms a cyst and/or oocyst.
  • the parasite and/or the virus is comprised in the gastrointestinal system such as the alimentary tract and/or respiratory system of the subject.
  • the virus is selected from rotaviruses, adenoviruses, coronaviruses, Hepatitis A, Hepatitis E, Norovirus, Enterovirus and Poliovirus.
  • the parasite is selected from coccidiosis and giardiasis.
  • composition is an antiviral nasal spray.
  • the present invention provides a composition comprising at least one Cl -Cl 2 organic acid and/or its salts in combination with an iron component, Ceylon cinnamon and B-vitamins and wherein the organic acid is a carboxylic acid with acidic properties.
  • C1-C12 organic acid refers to a fatty acid compound comprising from 1 carbon atom to 12 carbon atoms and having acidic properties.
  • Acidic property is defined herein as a molecule that can donate a proton to another molecule according to Bronsted definition of acids, Bronsted, J. N. (1923).
  • Cl -Cl 2 carboxylic acids are selected from short chained fatty acids (SCFA): formic acid (Cl), acetic acid (C2), Propionic acid (C3), Butyric acid (C4), Fumaric acid (C4); Medium-chained fatty acids (MCFA): Sorbic acid (C6), Caprylic acid (C8) and Long-chained fatty acids (LCFA): Lauric acid (C12).
  • SCFA short chained fatty acids
  • Cl formic acid
  • C2 acetic acid
  • Propionic acid C3
  • Butyric acid C4
  • Fumaric acid C4
  • MCFA Medium-chained fatty acids
  • MCFA Sorbic acid
  • Caprylic acid C8
  • LCFA Long-chained fatty acids
  • At least one of the carboxylic acids is formic acid and its salt.
  • the fatty acids are selected from Caprylic acid (C8), Sorbic acid (C6), formic acid (Cl), Propionic acid (C3), Butyric acid (C4), acetic acid (C2) and any combinations thereof.
  • the present composition comprises Cinnamon, Sodium Caprylate, Potassium Sorbate, Sodium Formate, Sodium Butyrate, Sodium Propionate and any combinations thereof in a dietary supplement for increasing virus resistance in a subject wherein the virus is comprised in the gastrointestinal system such as the alimentary tract and/or respiratory system and wherein the virus is selected from rotaviruses, adenoviruses, coronaviruses, Hepatitis A, Hepatitis E, Norovirus, Enterovirus and Poliovirus.
  • the composition comprises cinnamon, Sodium Caprylate, Potassium Sorbate, Iron Fumarate, Sodium Formate, Sodium Butyrate, Sodium Acetate, Sodium Propionate and any combinations thereof
  • Ceylon cinnamon as applied herein is bark from the Cinnamomum verum tree. Ceylon cinnamon from the Cinnamomum verum tree is often called true cinnamon and comprises lower amount of the toxin coumarin compared to Cassia cinnamon. The most produced cinnamon oil comes from Cassia cinnamon. Ceylon cinnamon is used herein.
  • Cinnamon oil can be made from either the bark or the leaves which will also give different ratios between the different essential oils. The composition of these two is very different in relation to the relationship between the different essential oils.
  • Cisa cinnamon contains approx. 250x more coumarin which in excessive doses can be toxic to the liver and kidneys. Too high doses of coumarin can also prevent Vitamin K synthesis in the gut and "Vitamin K bleeding deficiency" The toxic effects of Coumarin probably affect most people.
  • Cinnamon oil from leaves often contains a lot of eugenol and very little cinnamaldehyde, while it is the other way around when using bark.
  • Cinnamaldehyde has health-promoting effects by reducing the activity of important enzymes that trigger inflammatory reactions and allergic reactions.
  • EP 1 691 626 Bl discloses recommended amounts of B6, B12, B9 and Fe for human and animals to be included in the composition of the present invention.
  • viruses that are highly dependent on the fecal- oral route include Hepatitis A, Hepatitis E, Norovirus, Corona viruses (especially feline and equine coronaviruses), Enterovirus, Poliovirus and Rotavirus.
  • Decrease infectivity is the reduction of a virus or parasites ability to infect a cell in a subject, i.e. increasing virus or parasitic resistance.
  • Some of the most common causes for protozoan parasitic diarrhoea in dogs and cats include coccidiosis and giardiasis.
  • Isospora and Cryptosporidium species are two of the most common causes of clinical manifestation of coccidiosis in dogs and cats.
  • Other species may include Besnoitia, Toxoplasma, Hammondia and Sarcocystis.
  • Coccidian parasites are known for their infectious oocysts with an obligate fecal-oral route of infection.
  • Giardia parasites are another protozoan parasite with similar presentation of symptoms, however their life cycle do not include an oocyst.
  • Wild and farmed fish are also sometimes infected with viruses and parasites that has a hard-shelled life cycle stage. Examples include many coccidian parasites like Calyptospora, Goussia, Eimeria, Epieimeria, Cryptosporidium, Crystallospora, and Octosporella(fungi).
  • coccidian parasites like Calyptospora, Goussia, Eimeria, Epieimeria, Cryptosporidium, Crystallospora, and Octosporella(fungi).
  • coccidiosis in farmed fish in Norway seems to be a problem rather in lumpfish than in other farmed fish like atlantic salmon and rainbow trout.
  • Atlantic salmon and rainbow trout (salmonids)
  • several viral diseases poses a threat to the industry.
  • Cardiomyopathy syndrome Pancreas disease, Infectious salmon anemia, infectious pancreatic necrosis, Heart and skeletal muscle inflammation, Viral hemorrhagic septicaemia, Infectious hematopoietic necrosis and Salmon gill pox virus.
  • protozoan diseases There are many different antiprotozoal agents commercially available. This is a class of pharmaceuticals used in the treatment of protozoan diseases. Some of the most important protozoan diseases include amebiasis, giardiasis, cryptosporidiosis, microsporidiosis, malaria, babesiosis, trypanosomiasis, Chagas disease, leishmaniasis and toxoplasmosis. Currently, many of the treatments for these infections are limited by their toxicity and present invention may reducing the risk of and/or aid in the treatment of these.
  • composition comprising as the basic component at least one C1-C12 organic acid and/or its salt, an iron component, Ceylon cinnamon and B-vitamins in 0-200mg/g dry matter and in amounts corresponding to at least that which theoretically can be consumed during metabolism of the COOH- groups present.
  • composition also contains a desiccant and an antioxidant.
  • composition may also be administered in a suspension with pH amounting to 2-7.5.
  • the composition contains 66-100% of one or more C1-C8 organic acids and/or its salts.
  • the composition is characterized by an iron component consisting of 0-3.5% (w/w) iron, and the component preferably used is ferrous fumarate.
  • composition may also contain B-vitamins in amounts of 0- 200mg/g dry weight of the composition, wherein 0-10 mg/g Bl, 0-25mg/g B2, 0- 40mg/g B3, 0-25mg/g B5, 0-60mg/g B6, 0-25mg/g B7, 0-60mg/g B9 and 0-250pg/g B12.
  • composition is characterized by 0-6% cinnamon, preferably from the plant Cinnamomum vera.
  • composition is characterized by 0-6% w/w desiccant, preferably Silicone dioxide and/or Magnesium oxide.
  • composition is characterized by 0-1% w/w antioxidant, preferably Vitamin C or Vitamin E.
  • composition is used to treat or to aid in treatment against infection by parasites that contain hard-shelled life cycle stages like cysts and oocysts.
  • composition is used to treat or aid in treatment against infection by viruses with an affinity towards gastrointestinal system and respiratory system like rotaviruses, adenoviruses, coronaviruses, etc.
  • composition is administrated by a daily dosage which may be applied, is in the range 25-500mg/kg bodyweight or 0.5-10g per 20kg body weight.
  • composition is administration by inhalation or intranasal application in the state of powder, suspension, gel-suspension, supplemented directly to food/feed or is swallowed as a tablet or capsule.
  • the main feature of the composition according to the invention comprises a basic component having at least one C1-C8 organic acid and/or its salt comprising at least formic acid, an iron component preferably iron fumarate, Ceylon cinnamon, and B6, B9 and B12-vitamins in the range from 0 to 200mg/g dry weight of the composition and in an amount corresponding to at least that which theoretically can be consumed during metabolism of the COOH-groups present and wherein the organic acid is a carboxylic acid having acidic properties and wherein the carboxylic acids are fatty acids and wherein the total amount of organic acids is at least 66% (w/w) by weight based on dry weight of the composition.
  • the composition in addition may comprise antioxidants and desiccants and further components depending on its intended use wherein these further components don’t change the effect of the composition.
  • Mortality in fish may be caused by several factors including viruses and parasites as discussed above.
  • a study conducted on 600 Atlantic salmon showed a 100% reduction in mortality rate.
  • the study design was constructed as follows:
  • Feed A Control carrier pellet with no additives
  • Feed B Carrier pellet with 1.5% of present invention comprising Sodium diformate, Calcium butyrate and Sodium caprylate.
  • the fish were 40 grams and adapted to sea water at starting point.
  • Results showed a 5% mortality rate in the control group after 9 and 10 weeks compared to zero mortality in group with carrier pellet. Growth and length were significantly improved within the first 5 weeks along with hepatic weight and intestinal tissue damage significantly reduced as well.
  • Non-responders to placebo were crossed to present invention.
  • the present invention contains salts of organic acids with established antibacterial effects, however results may suggest an even wider efficiency across viruses and parasites. Especially those involved in gastrointestinal illness.
  • Oocysts were exposed to hypochlorite for 10 min on ice to remove bacterial contaminants and then washed twice in PBS before being resuspended in RPMI (a growth medium used in cell culture) at either pH 7 or at pH 3, the latter with or without (controls) different components from present invention. Single compounds were tested at concentrations of 5 mg/mL, and combinations with sodium formate at 2.5 mg/mL for each compound.
  • the experimental set-up was as shown in Figure 1 (below).
  • the study was run in triplicate (three individual set-ups), with each set-up consisting of technical triplicates of each experimental procedure.
  • the copy number results obtained are shown in Table 1, and indicate the mean copy numbers of the qPCR target gene of C. parvum from the three replicate experiments. Higher numbers thus indicate greater numbers of parasites following infection and replication. Lower numbers indicate either reduced infection and/or reduced replication.
  • Table 1 Percentages of inhibition of Cryptosporidium parvum infection and/or replication following incubation with different components, as related to incubation in RPMI pH 3 in the absence of these compounds.
  • a laboratory study was conducted to test the effect of powder from cinnamon bark from Ceylon cinnamon on the infectivity of a virus (Experiment A and B) and to test the effect on the infectivity of a virus, using a combination of the following organic acids: Sodium format, Calcium format, iron fumarate and potassium sorbate (experiment C and D).
  • the virus used for the experiments was Bovine Coronavirus (BCoV).
  • BCoV Bovine Coronavirus
  • the infectivity of the virus was tested with the use of human colorectal adenocarcinoma cells (HCT-8) and the infectivity of the virus was evaluated using microscope.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Polymers & Plastics (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Food Science & Technology (AREA)
  • Animal Husbandry (AREA)
  • Zoology (AREA)
  • Mycology (AREA)
  • Birds (AREA)
  • Inorganic Chemistry (AREA)
  • Nutrition Science (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Botany (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biotechnology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Insects & Arthropods (AREA)
  • Communicable Diseases (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Physiology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Medical Informatics (AREA)
  • Microbiology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

La présente invention concerne une combinaison de différents composants et son utilisation, l'invention comprenant comme composant de base au moins un acide organique et/ou son sel, un composant de fer, de la cannelle de ceylan et des vitamines B. La combinaison peut également contenir un déshydratant et un antioxydant. La combinaison aura un pH situé dans la plage de 2,0 à 7,5 lorsqu'elle est dissoute dans une solution et est destinée à tous les animaux y compris les primates. La présente combinaison peut être utilisée dans la production d'aliments pour animaux, mais peut également être administrée au moyen d'autres applications ou comme elle est. Le dosage quotidien qui peut être appliqué, se situe dans la plage de 25 à 500 mg/kg de poids corporel ou de 0,5 à 10g pour 20 kg de poids corporel.
EP23717837.1A 2022-03-08 2023-03-08 Composition pour le traitement d'une infection parasitaire ou virale dans un tube digestif et/ou respiratoire Pending EP4489585A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
PCT/EP2022/055947 WO2023169664A1 (fr) 2022-03-08 2022-03-08 Composition pour le traitement d'une infection parasitaire ou virale dans des voies digestives et/ou respiratoires
PCT/EP2023/055944 WO2023170183A1 (fr) 2022-03-08 2023-03-08 Composition pour le traitement d'une infection parasitaire ou virale dans un tube digestif et/ou respiratoire

Publications (1)

Publication Number Publication Date
EP4489585A1 true EP4489585A1 (fr) 2025-01-15

Family

ID=81074345

Family Applications (1)

Application Number Title Priority Date Filing Date
EP23717837.1A Pending EP4489585A1 (fr) 2022-03-08 2023-03-08 Composition pour le traitement d'une infection parasitaire ou virale dans un tube digestif et/ou respiratoire

Country Status (2)

Country Link
EP (1) EP4489585A1 (fr)
WO (2) WO2023169664A1 (fr)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4559476A1 (fr) * 2023-11-24 2025-05-28 O'Briain, Killian Composition comprenant de la lactoperoxidase et un sel d'iode, et son utilisation pour le traitement du syndrome d'ulcère gastrique équin
US12311014B1 (en) 2023-11-24 2025-05-27 Killian O'BRIAIN Composition and use thereof for the treatment of equine gastric ulcer syndrome

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5858356A (en) * 1995-12-21 1999-01-12 Abbott Laboratories Lactobacillus acidophilus to inhibit cryptosporidiosis in mammals
NO320989B1 (no) 2003-12-05 2006-02-20 Pigeon Vitality As Fôrtilsatsstoff inneholdende en karboksylsyre og/eller dens salt som basis komponent i tilsatsstoffet.
US10478493B2 (en) * 2015-08-31 2019-11-19 Stolle Milk Biologics, Inc. Method of treating protozoal gastrointestinal disorders in immunocompromised patients

Also Published As

Publication number Publication date
WO2023169664A1 (fr) 2023-09-14
WO2023170183A1 (fr) 2023-09-14

Similar Documents

Publication Publication Date Title
Yang et al. Impact of essential oils and organic acids on the growth performance, digestive functions and immunity of broiler chickens
JP4664678B2 (ja) 抗菌性組成物および使用のための方法
BE1019290A5 (nl) Voedingsupplement omvattende oligosachariden en middellange keten vetzuren.
Iqbal et al. Effect of essential oil and organic acid on performance, gut health, bacterial count and serological parameters in broiler
Li et al. Effects of antimicrobial peptides on the growth performance, antioxidant and intestinal function in juvenile largemouth bass, Micropterus salmoides
WO2023170183A1 (fr) Composition pour le traitement d'une infection parasitaire ou virale dans un tube digestif et/ou respiratoire
Yu et al. Effect of Supplementing a Blend of Essential Oils on the Growth Performance, Carcass Characteristics, Meat Quality, Serological Parameters and Gut Health in Broiler Chickens.
AU770826B2 (en) Natural physiologically active substances efficacious against fish diseases and fish feeds containing the same
CN109452490A (zh) 一种防治由霉菌毒素中毒引起的鸡肌胃炎、腺胃炎的饲料添加剂及其应用
EP1765318A2 (fr) Acides gras a chaine moyenne pouvant etre utilises comme agents antimicrobiens
CA3001310C (fr) Aliment pour oiseaux et en particulier aliment pour la volaille, comprenant des derives capsaicinoides synthetiques et utilisation de cet aliment a des fins de prophylaxie ou de t raitement d'une infection par la salmonelle
Mimoune et al. Zootechnical, bacteriological, and histometrical effects of a combination mycotoxin binder-acidifier in broiler chickens
CN117377469A (zh) 用于抗病毒感染的应用的壬酸
Naeem et al. Importance and promotion of gut health in broilers through dietary interventions
US20210321638A1 (en) Animal feed and methods to provide such feed
JP2001008636A (ja) 感染症防止用飼料組成物
Van der Heijden et al. Assessment of the antihistomonal effect of paromomycin and tiamulin
US20030162834A1 (en) Natural physiologically active material effective on fish diseases and fish food containing the material
RU2832334C1 (ru) Способ кормления бройлеров в условиях теплового стресса
US20250082732A1 (en) Anti-microbial and anti-inflammatory compositions and methods for treating enteric diseases in animals
Samantaray et al. Effect of dietary supplementation of organic acids on performance of broilers fed Salmonella gallinarum contaminated feed
Akyıldız et al. Efficacy of herbal extracts on growth performance, serum biochemistry and intestinal selected bacterial population in broilers.
PALASH EFFECT OF NON-ANTIBIOTIC GROWTH PROMOTER IN BROILER PRODUCTION
CN120916758A (zh) 用于治疗和/或预防家禽中球虫病诱导的病况的包含胍基乙酸的组合物
EA043988B1 (ru) Биологически активная кормовая добавка и способ ее получения

Legal Events

Date Code Title Description
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: UNKNOWN

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20240918

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC ME MK MT NL NO PL PT RO RS SE SI SK SM TR

DAV Request for validation of the european patent (deleted)
DAX Request for extension of the european patent (deleted)